The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation - PubMed (original) (raw)
Comparative Study
. 2002 Nov 1;100(9):3108-14.
doi: 10.1182/blood-2002-02-0506.
Richard Lush, Jamie Cavenagh, Donald W Milligan, Steven Schey, Anne Parker, Fiona J Clark, Linda Hunt, John Yin, Steven Fuller, Elisabeth Vandenberghe, Judith Marsh, Timothy Littlewood, Graeme M Smith, Dominic Culligan, Ann Hunter, Rajesh Chopra, Andrew Davies, Keiren Towlson, Catherine D Williams
Affiliations
- PMID: 12384406
- DOI: 10.1182/blood-2002-02-0506
Free article
Comparative Study
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation
David I Marks et al. Blood. 2002.
Free article
Abstract
We describe the toxicity and efficacy of donor lymphocyte infusions (DLIs) given to 81 patients (median age, 50 years) after reduced-intensity conditioning (RIC) transplantations performed at 16 centers in the United Kingdom. The diseases treated included non-Hodgkin lymphoma (NHL; n = 29), chronic myeloid leukemia (CML; n = 12), myeloma (n = 11), acute myeloid leukemia (AML; n = 10), and chronic lymphocytic leukemia (CLL; n = 9). Eighty-eight percent received stem cells from sibling donors. The patients received 130 infusions (median, 1; range, 1-4). Indications for DLI were unsatisfactory response/disease progression in 51 patients, mixed chimerism in 18, preemptive in 10, and other in 2. Graft hypoplasia was uncommon (11%). Grade II to IV graft-versus-host disease (GVHD) occurred in 23 of 81 patients (28%) and limited and extensive chronic GVHD in 5 of 69 and 18 of 69 evaluable patients (total incidence 33%). Conversion from mixed to full donor chimerism occurred in 19 of 55 evaluable patients (35%) at a median of 48 days after the DLI; partial responses occurred in 6 patients (total response rate 45%). Eighteen of 51 (35%) patients with measurable disease after stem cell transplantation had a complete response (2 molecular), and 5 a partial response (total response rate 45%). Eleven of 17 evaluable complete responders had full donor chimerism. Eight of 13 patients with follicular NHL had complete responses as did 4 of 12 patients with CML. Clinical and chimeric responses correlated strongly with acute and chronic GVHD. Forty-seven patients (58%) survive at a median of 508 days after transplantation (range, 155-1171 days) with a median Karnofsky score of 90. Thirty-four patients (42%) died at a median of 211 days after transplantation with the major causes being progressive disease (26%) and GVHD (9%). Further systematic studies are required to determine the efficacy and optimum use of DLI for patients with each disease treated by nonmyeloablative stem cell transplantation.
Similar articles
- Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
Pérez-Simón JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, García-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, Parker A, Leon A, Yong K, Sureda A, Hunter A, Sierra J, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S; Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation. Pérez-Simón JA, et al. Blood. 2002 Nov 1;100(9):3121-7. doi: 10.1182/blood-2002-03-0701. Blood. 2002. PMID: 12384408 - Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR, Taghipour G, Schmitz N; Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Robinson SP, et al. Blood. 2002 Dec 15;100(13):4310-6. doi: 10.1182/blood-2001-11-0107. Epub 2002 Aug 15. Blood. 2002. PMID: 12393626 - In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S. Kottaridis PD, et al. Blood. 2000 Oct 1;96(7):2419-25. Blood. 2000. PMID: 11001893 Clinical Trial. - Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT. Dreger P, et al. Leukemia. 2003 May;17(5):841-8. doi: 10.1038/sj.leu.2402905. Leukemia. 2003. PMID: 12750695 Review.
Cited by
- Seven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: A case report and review of literature.
Deng B, Gao R, Yang B, Lei WB, Xue MF, Wang JS, Zhao P. Deng B, et al. World J Clin Cases. 2024 Aug 26;12(24):5604-5612. doi: 10.12998/wjcc.v12.i24.5604. World J Clin Cases. 2024. PMID: 39188601 Free PMC article. - Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.
Pang Y, Holtzman NG. Pang Y, et al. Best Pract Res Clin Haematol. 2023 Jun;36(2):101475. doi: 10.1016/j.beha.2023.101475. Epub 2023 May 11. Best Pract Res Clin Haematol. 2023. PMID: 37353287 Free PMC article. Review. - Optimizing Blood Stem Cell Transplants Through Cellular Engineering.
Soh KVQY, Hwang WYK. Soh KVQY, et al. Blood Cell Ther. 2022 Jan 14;5(1):1-15. doi: 10.31547/bct-2021-008. eCollection 2022 Feb 25. Blood Cell Ther. 2022. PMID: 36714264 Free PMC article. Review. - 60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.
Cieri N, Maurer K, Wu CJ. Cieri N, et al. Cancer Res. 2021 Sep 1;81(17):4373-4384. doi: 10.1158/0008-5472.CAN-21-0301. Epub 2021 Jun 9. Cancer Res. 2021. PMID: 34108142 Free PMC article. Review. - Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies.
Bernasconi P, Borsani O. Bernasconi P, et al. Cancers (Basel). 2019 Dec 25;12(1):69. doi: 10.3390/cancers12010069. Cancers (Basel). 2019. PMID: 31881776 Free PMC article. Review.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources